Improved Outcome in Pediatric Relapsed Acute Myeloid Leukemia: Results of a Randomized Trial on Liposomal Daunorubicin by the International BFM Study Group
Gertjan J.L. Kaspers(Emma Kinderziekenhuis), Ursula Creutzig(Medizinische Hochschule Hannover), Liisa Hovi(Stichting Kinderoncologie Nederland), Sy Ha(Queen Mary University of London), Guy Leverger(Sorbonne Université), Owen Smith(Trinity College Dublin), Carmelo Rizzari(Hôpital Saint-Michel), Petr Smíšek(Stichting Kinderoncologie Nederland), Michael Dworzak(St. Anna Children's Cancer Research Institute), Henrik Hasle(Aarhus University Hospital), R. Y. J. Tamminga(University Medical Center Groningen), Bassem I. Razzouk(Peyton Manning Children’s Hospital at St.Vincent), Dirk Reinhardt(Society of Paediatric Oncology and Haematology), H. Armendariz(Instituto Argentino de Diagnóstico y Tratamiento), Yves Bertrand(Université Claude Bernard Lyon 1), Brenda Gibson(Royal Hospital for Children), Alexei Maschan(Stichting Kinderoncologie Nederland), Batia Stark(Schneider Children's Medical Center), Martin Zimmermann(Stichting Kinderoncologie Nederland), Olga Aleinikova(Stichting Kinderoncologie Nederland)
Cited by 233
Related Papers
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel
|Blood|2012|575
Optimization of Chemotherapy for Younger Patients With Acute Myeloid Leukemia: Results of the Medical Research Council AML15 Trial
|Journal of Clinical Oncology|2013|415
Collaborative Efforts Driving Progress in Pediatric Acute Myeloid Leukemia
|Journal of Clinical Oncology|2015|383
Transfusion guidelines for neonates and older children
|British Journal of Haematology|2004|371